Imaging guided photothermal therapy using iron oxide loaded poly(lactic acid) microcapsules coated with graphene oxide

A novel multifunctional theranostic agent has been successfully fabricated by loading iron oxide nanoparticles into poly(lactic acid) (PLA) microcapsules followed by surface functionalization with graphene oxide. Both in vitro and in vivo experiments proved that the resulting microcapsules could ser...

Full description

Saved in:
Bibliographic Details
Published in:Journal of materials chemistry. B, Materials for biology and medicine Materials for biology and medicine, 2014-01, Vol.2 (2), p.217-223
Main Authors: Li, Xiao-Da, Liang, Xiao-Long, Yue, Xiu-Li, Wang, Jin-Rui, Li, Chang-Hui, Deng, Zi-Jian, Jing, Li-Jia, Lin, Li, Qu, En-Ze, Wang, Shu-Min, Wu, Chun-Long, Wu, Hua-Xing, Dai, Zhi-Fei
Format: Article
Language:English
Subjects:
Cancer
Contrast agents
Graphene
Imaging
Iron oxides
Magnetic fields
Oxides
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A novel multifunctional theranostic agent has been successfully fabricated by loading iron oxide nanoparticles into poly(lactic acid) (PLA) microcapsules followed by surface functionalization with graphene oxide. Both in vitro and in vivo experiments proved that the resulting microcapsules could serve as contrast agents to simultaneously enhance ultrasound, magnetic resonance and photoacoustic imaging. The composite microcapsules show good biocompatibility and rapid response to magnetic fields. Due to the strong absorption of the near-infrared light, the composite microcapsules could efficiently kill cancer cells upon NIR laser irradiation. In addition, it was found that such a photothermal effect could be obviously enhanced by applying an external magnetic field. In a nutshell, this multifunctional microcapsule can be developed as a promising platform that integrates multimodality imaging and therapy capabilities for effective cancer theranostics.
ISSN:2050-750X
2050-7518
DOI:10.1039/c3tb21281e